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GPS2 DEPENDENT REGULATION OF 
AKT ACTIVATION IN PRE-ADIPOCYTES 
AARON SHAMBLEY 
ABSTRACT 
 Through endocrine and exocrine functioning, physiological needs are 
communicated to body systems. Physiological need is met through the actions of 
intracellular signaling cascades and calibrated through an extensive network of regulatory 
cross talk within the cells of a given tissue.  
The insulin receptor belongs to a family of perhaps one of the most well studied 
family of dual receptor and tyrosine kinases (RTK). The signaling cascade downstream 
of the insulin RTK can be initiated through Insulin or growth factor ligand binding and 
bears growing relevance to the projected epidemic of obesity related illness and 
associated cancers. The primary function of the post-prandial insulin response is to 
support nutrient uptake and storage.  
Insulin (IS), Insulin-Like Growth Factor (IGF), and Epidermal Growth Factors 
(EGF) contribute to glucose metabolism, energetic homeostasis, and anabolic 
applications through effector kinases downstream of activated (phosphorylated) insulin 
receptor substrates (IRS). Protein Kinase B (AKT) kinase is one such cytosolic effector 
known to be of critical importance to anabolic metabolism and general cell survival. 
Under normal circumstances, AKT activity is dependent upon dual phosphorylation 
events known to occur at the plasma membrane. 
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In an attempt to better understand the mechanism of AKT recruitment to the 
plasma membrane, earlier experiments reported that IRS stimulation by Insulin-Like 
Growth Factors (IGF) and Epidermal Growth Factors (EGF) resulted in downstream 
poly-ubiquitination and subsequent activation of the AKT kinase.  This sequence of post-
translational modification events suggested that non-proteolytic AKT ubiquitination, 
accomplished by the E2 Ubiquitin Conjugating enzyme (UBC13), was an important 
mediator of AKT activation.  
Through subsequent experimentation, it was determined that non-proteolytic 
ubiquitination was a necessary step for AKT activation following IRS activation by 
Insulin. Furthermore, the same two sites previously described in the context of IGF/EGF 
signaling were exploited through targeted mutagenesis and shown to synergistically 
regulate AKT translocation to the plasma membrane. Mutant AKT variants with a single 
mutation to either ubiquitination site resulted in partial knock down of phosphorylated 
AKT (pAKT), while variants with double mutations resulted in a complete loss of pAKT 
detection.  
Under physiologic conditions UBC13 activity can be antagonized by a small 
multifunctional protein called G-Protein Pathway Suppressor 2 (GPS2). Bearing the 
kinetics of an endogenous inhibitor, GPS2-mediated regulation directly inhibits the 
ubiquitin conjugating activity of the enzyme; thereby restricting AKT non-proteolytic 
poly-ubiquitination and antagonizing the insulin signaling network through a conserved 
mechanism. In accordance with this role, we have previously shown that GPS2 presence 
in adipocytes modulates systemic metabolism by restricting the activation of insulin 
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signaling during the fasted state, whereas in absence of GPS2, the adipose tissue is more 
efficient at lipid storage, and obesity becomes uncoupled from inflammation and insulin 
resistance.   
As we are just beginning to unravel the regulatory network governing the cellular 
response to nutrient excess and pro-growth signaling, it remains unclear whether UBC13 
activity is universally engaged in AKT translocation and activation. Here we have 
focused on the mitochondrial pool of AKT and investigated its regulation. Our findings 
add to the growing body of knowledge by demonstrating that in pre-adipocytes 
mitochondrial AKT is activated, in a UBC13-dependent fashion, following insulin 
stimulation. We also show that GPS2-mediated inhibition of UBC13 equally antagonizes 
AKT activation in different subcellular compartments, and that mitochondrial AKT 
activation is partially Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) dependent. 
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INTRODUCTION  
Nutrition and Metabolism: What it is and Why it’s Important  
The World Health Organization defines “Nutrition” as the intake of food in 
relation to the body’s physiological, dietary, and energetic needs [1]. Nutritional science 
can be broadly classified as the study of how the human body responds to and utilizes 
nutrients through catabolic and anabolic metabolism.  
Metabolism and the biochemical mechanisms by which a substance can be 
transformed or interconverted have re-emerged as major focal points in the treatment of 
disease. Following the advent of technological advancement and innovation, nutritional 
science and metabolic research have deepened our epidemiological understanding and 
underscored critical chokepoints in pathogenesis which can be exploited by future 
targeted therapeutics.  
Nutrition and Obesity  
A healthy eating pattern is one that provides enough of each essential nutrient 
from nutrient-dense foods, contains a variety of foods from all of the basic food groups, 
and focuses on balancing calories consumed with calories expended to help you achieve 
and sustain a healthy weight [2]. 
In the field of nutrition, total energy expenditure (TEE) is determined by Basal 
Metabolic Rates (BMR), physical activity, and the thermic effect of food (TEF). BMR 
represents an individual’s basal metabolic rate of expended energy per hour and 
contributes most towards TEE. Physical activity is the most variable determinant of TEE; 
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it is most heavily influenced by intrinsic personal choices and extrinsic obesogenic 
environments or circumstance. TEF can be defined as the energetic expenditure 
associated with macronutrient digestion, absorption, and metabolite utilization; primarily 
towards Adenosine Tri-Phosphate (ATP) production. Of the three macronutrient 
classifications, Dietary proteins have the highest (TEF) while and will require more 
energy to metabolize. Dietary Fats and Carbohydrates have lower TEF’s and can be 
metabolized with less energetic expenditure. The resultant TEE is represented by a 
positive or negative non-zero value representing a net gain or net loss of energy 
expressed in Kilocalories (kCal) [3].  
Trends in the directions and magnitudes of the day to day TEE can be partially 
reflected in an imperfect measurement of the total Body Mass index (BMI). Consistent 
energetic intake with minimal energy expenditure normally correlates with greater BMI 
and adiposity. BMI is derived from the division of weight in kilograms by the height in 
meters squared; rounded to 1 decimal place [4]. As a standard of energetic homeostasis 
and metabolic health, adults with BMI equal to or greater than 30 are classified as obese 
and metabolically unhealthy. Obesity in youth is defined as a BMI of greater than or 
equal to the age- and sex-specific 95th percentile of the 2000 Centers for Disease Control 
and Prevention Growth Charts; From 2015-2016, the prevalence of obesity was 39.8% in 
adults and 18.5% among youth [4]. 
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Metabolism and Obesity 
Nutrient digestion begins in the mouth and stomach where mechanical force and 
coordinated enzymatic secretions reduce macronutrients like proteins, starches, and fats 
to a slushy nutrient broth called Chyme. Chyme contains the monomeric Amino Acids 
from protein, glucose from complex carbohydrates, as well as free fatty acids and 
glycerol subunits from lipids; all of which gain access to general circulation through 
substrate specific means and trigger the post prandial insulin response from Pancreatic 
beta cells [7].  
The primary metabolite derived from dietary intake is Glucose – a versatile 
carbohydrate which can be interconverted to support other cellular processes, catabolized 
to generate energy in form of ATP via glycolysis and oxidative respiration, or used 
directly by the pancreas as an indicator of systemic glucose metabolism and homeostasis. 
When serum nutrients are low, Glucagon is secreted by Pancreatic Alpha Cells; this 
action promotes hepatic glycogenolysis, hepatic gluconeogenesis, and lipolysis from 
White Adipose Tissue (WAT). Glucagon ultimately acts as a safeguard against 
hypoglycemia when serum glucose falls. Conversely when serum nutrients are high, 
insulin is secreted by Pancreatic Beta Cells promoting nutrient storage and uptake while 
safeguarding against hyperglycemia (Figure 1) [6]. 
Towards the goal of lowering blood osmolality, insulin release promotes Glucose 
Transporters (GLUT4) translocation to the plasma membranes of muscle and WAT 
which allow for nutrient uptake, and trigger hepatic glycogenesis. Glucose in excess of 
glycogen storage capacity will be repackaged into very low-density lipoproteins (VLDL) 
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particles as Triglycerides and exported to White Adipose Tissue. As VLDL particles 
enter the capillary system on their way to WAT, the post prandial insulin secretion 
stimulates Hormone Sensitive Lipases (HSL) embedded in capillary walls. Activated 
HSL ruptures VLDL particles resulting in nutrient release. Insulin bound receptors at 
WAT trigger the recruitment of transporter proteins to the plasma membrane and 
facilitate lipogenesis downstream of the activated AKT Kinase [6, 7, 8]. 
 
Figure 1: Systemic Glucose Regulation. 
 
The Glucose Stimulated Insulin Cascade 
 Glucose-Stimulated Insulin Secretion (GSIS) is the principle mechanism of 
insulin secretion [8], and glucose metabolism is the most important physiological event 
known to stimulate insulin gene transcription and mRNA translation of Preproinsulin [9]. 
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As a biologically inactive precursor, Preproinsulin is synthesized as single polypeptide 
and contains a 24-residue signal peptide which directs the nascent Preproinsulin to the 
Endoplasmic Reticulum (ER). The signal peptide is cleaved while the Proinsulin 
completes translation into ER lumen. Protein disulfide isomerases will catalyze disulfide 
bridge formation as Proinsulin folds into the proper configuration before it is exported to 
the Golgi Network [10]. As Proinsulin is passed through the Golgi Body, Endopeptidases 
(Prohormone Convertase 1 and 2) and Carboxypeptidase E excise the C-Peptide yielding 
a biologically active Insulin molecule spanning 51 amino acids and weighing 5.8kDa 
[11]. Depending on energetic homeostasis and systemic metabolic demand, insulin will 
either be stored in the Beta cell as insoluble hexameric granules or released as insulin 
monomers into circulation (Figure 2) [11].  
Peptide hormones Insulin and Insulin-Like Growth Factors (IGF1/2) are 
commonly released under conditions of nutrient excess and need to bind transmembrane 
receptors because of their inability to pass through the plasma membrane. The Insulin 
Receptor (IR) and Classic Insulin-Like Receptors (ILR) belong to a superfamily of ligand 
activated kinases. When bound, these receptors enhance their affinity to ATP through 
dimerization and auto-phosphorylate Tyrosine residues. Phospho-tyrosine residues (pTyr) 
along an active, ligand bound receptor (IR/ILR) function as docking sites for Insulin 
Receptor Substrates (IRS) bearing steroid receptor Co-activator (SH2) homology  and 
phosphor-tyrosine binding domains (PTB) [12, 13, 48]. IRS represents a key class of 
adaptor proteins acting to bridge Insulin and IGF to the PI3K/AKT signaling cascade. 
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Figure 2: Constituents of PreProInsulin. 
 
Epidermal Growth factor (EGF) is classified as a polypeptide growth hormone 
whose mechanism mirrors that of Insulin and IGF. Ligand binding (EGF) leads to 
dimerization, auto-phosphorylation, and most commonly RAS/RAF activation; a pathway 
related to and mutually influenced by the PI3K/AKT signaling cascade. However, the 
Dimerization of ErbB2 with ErbB3 or ErbB4 directly evokes PI3K induction of AKT [12, 
13, 15, 48]. Thus, Insulin and Growth Factor stimulation (IGF/EGF) converge on PI3K 
when initiating intracellular signal propagation (Figure 3). 
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Figure 3: Insulin, IGF, and EGF converge on PI3K 
 
Phosphoinositide 3-Kinase (PI3K) belong to a phylogenetically conserved family 
of lipid kinases characterized by PTB regulatory subunits (p85) and catalytic domains 
(p110). Through p85, PI3K associates with IRS or ErbB receptors and catalyzes the 
production of second messengers from the plasma membrane. Active p110 generates 
phosphatidylinositol-3,4,5-triphosphate (PI[3,4,5]P3 or PIP3 from membrane bound 
phosphatidylinositol-4,5-bisphosphate (PI[4,5]P2 or PIP2) by phosphorylating D3 
position of inositol-based substrates [48, 13]. The creation of PIP3 by PI3K at the plasma 
membrane initiates the coordinated translocation of cytosolic Protein Kinase B (AKT) 
and 3-phosphoinositide-dependent protein kinase 1 (PDPK1 or PDK1); each bearing high 
affinity for PIP3 via their respective Pleckstrin Homology Domains [13, 14, 27] (Figure 
4).   
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Figure 4: The Insulin-PI3K-AKT Cascade. 
 
In the absence of PIP3, PDK1 is unable to phosphorylate wild-type AKT, even 
though it can phosphorylate and activate a mutant AKT lacking the PH domain [14]. 
These findings suggest that PIP3 removal impairs the coordinated translocation of AKT 
and PDK1 to the plasma membrane in insulin stimulated cells, and the PH domain 
functions as a shield against PDK1 phosphorylation thereby preventing inappropriate 
AKT activity.  
Cellular AKT (c-AKT) is a heavily regulated pro-survival serine/threonine kinase 
characterized [38] by N-Terminal PH domain, an ATP binding site, an activation loop 
targeted whose Threonine at position 308 (T308) is targeted by PDK1 phosphorylation, 
and a hydrophobic motif containing an additional phosphorylation site at Serine-473 
(S473). Upon recruitment to the plasma membrane through mutual interactions with PIP3 
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second messengers, PDK1 partially activates AKT via phosphorylation [9, 13, 16, 30] 
(Figure 5). 
In addition to PI3K induction, c-AKT translocation and subsequent activation can 
be triggered from Gag-fusion or artificial myristoylation, indicating that membrane 
recruitment represents a limiting step for AKT activation [29]. The viral homolog of c-
AKT is the viral oncoprotein v-AKT and results from the fusion of c-Akt and a retroviral 
Group Antigen (Gag) protein [38]. Gag proteins represent one of three major proteins 
encoded within the retroviral genome which form RNA genome binding proteins and 
drive viral particle assembly when modified by attachment of the 14-carbon fatty acid 
myristate [39]. With the inclusion of an additional 21 amino acids derived from the 
translation of 63 nucleotides of the c-Akt 5′ untranslated region placed in phase between 
Gag and Akt. The myristoylation sites in the Gag sequence target Akt to the plasma 
membrane and results in high basal kinase activity [38]. 
To enhance AKT stability and gain the full range of pleiotropic activation, AKT 
(as pAKT-T308) precludes the actions of Tuberculosis Complex 2 (TSC2); thereby 
allowing Tuberculosis Complex 1 (TSC1) to facilitate the activation of the mammalian 
target of Rapamycin (mTOR) complex. The anabolic signaling of mTOR promotes 
protein synthesis and regulates the upstream insulin signaling network [9, 13, 16, 17, 18, 
30]. More specifically the rapamycin-insensitive complex 1 (mTORC1) activates 
initiation factors such as S6 kinase (S6K) and eukaryotic initiation factor 4E-binding 
protein-1 (4EBP1) [9] which initiate protein synthesis in the nucleus. As an AKT 
negative regulator, the S6K mTOR1 effector also migrates to the plasma membrane 
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where it participates in secondary inhibition and prevents overcompensation by AKT in 
response to insulin by targeting IRS1 for proteosomal degradation via phosphorylation [9, 
18]. Simultaneously, rapamycin-insensitive complex (mTORC2) phosphorylates Ser473 
of AKT and Protein Kinase-C (PKC) [9] resulting in full AKT activation and signal 
transduction in response to growth factor, insulin, and/or glucose. 
 
Figure 5: AKT, PDK1, SGK1, and S6K1 Structures. 
 
Glucose Restriction and Metabolic Adaptation  
The transient post prandial glucose response in healthy individuals is analogous to 
self-perpetuating IGF1 upregulation in the obese given that both indicate nutrient excess, 
and both trigger the cascade downstream of PI3K [5]. There exists a plethora of 
alternative mechanisms intended to satiate metabolic need and dampen severity of 
extracellular conditions which may compromise cell survival.  
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Under normal conditions, the proposed mechanism for mTORC2 activation [52, 
54] relies on PI3K and PIP3 production (Figure 6). Based on the known sequence of 
events that describe the Insulin/IGF/EGF-AKT-PI3K pathway, glucose restriction should 
limit PI3K, mTORC2, and AKT phosphorylation. This is accomplished by the 2 isoforms 
of TSC which exist as a heterodimeric negative regulator of mTOR and provides an 
additional layer of protection against inappropriate or inefficient energy expenditure in 
the fasted state (when AKT is supposed to be inactive) [32].  
 
Figure 6: mTORC2 Activation Mechanism. 
 
 However, even when challenged with glucose and/or Insulin and growth factor 
restriction, mTORC1 could be activated by PI3K through a parallel process of 
coordinated translocation and co-activation of PDK1, mTORC2, and Serum 
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Glucocorticoid Regulated Kinase-1 (SGK1). Like AKT, SGK1 is regulated by dual 
phosphorylation and functions as serine/threonine kinase which selectively inhibits 
Tuberous Sclerosis Complex 2 (TSC2) but not TSC1 [37, 51, 52, 53] (Figures 5 and 7).  
Figure 7: SGK1 Dependent Survival. 
 
 A translational study utilizing both murine and human samples used a targeted 
inhibitor against an isoform of PI3K’s p110 subunit previously shown to undergo de 
novo gain-of-function mutation that drive AKT hyperactivation in breast cancer. PI3K 
inhibition showed a significant but incomplete decrease in SGK1 activity. However, 
because SGK1 does not rely on PIP3, it remains active in the absence of PIP3. The article 
concludes PDK1-SGK1 interactions represent a viable PI3K and AKT independent 
alternative to mTORC1 activation and attribute sustained SGK1 activity to PIP3-
independent mTORC2 and PDK1. Taken together, this article outlines an alternative 
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network of AKT activation when challenged with glucose deprivation via PDK1 (pAKT-
T308) and PIP3-independent mTORC2 (pAKT-S473) [53]. 
It’s clear from the literature, the nexus around AMPK activation begins with high 
AMP/ATP, indicative of metabolic stress. Long term starvation should suppress AKT 
activity, maintain mTOR inhibition by TSC1/2, and limits cell cycle progression and 
proliferation through numerous nutrient sensing pathways and pro-apoptotic or 
autophagic programming [31, 32 35, 37, 51, 52, 53].   
In humans, Liver Kinase B1 (LKB1) also known as Serine/Threonine Kinase 11 
(STK11), is activated by nutrient sensing enzyme during periods of prolonged energetic 
paucity and activates AMP-Activated Protein Kinase (AMPK) through phosphorylation. 
AMPK is a trimeric, pleiotropic, master regulator of cellular metabolism with ubiquitous 
expression. Adenosine Tri-Phosphate (ATP) is the energetic currency derived from 
anabolic metabolism of glucose and its intermediaries through glycolysis and oxidative 
phosphorylation. AMP is a catabolic product of proteolytic digestion which can occur 
across the small intestines brush border or intracellularly through RNA degradation. The 
ratio between ATP and AMP is generally accepted as one of many reliable indicators of 
intracellular metabolism [31, 32 35, 37, 51, 52, 53, 55] (Figure 8). 
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Figure 8: AMPK Function and Regulation. 
 
Direct Adenosine Mono-Phosphate (AMP) binding enhances LKB1-dependent 
phosphorylation in vivo and confers resistance to phosphatases when bound to activated 
AMPK [55]. Alternatively, AMP can be converted into the second messenger cyclic-
AMP (cAMP); cAMP’s can be regulated by cAMP specific phosphodiesterase’s (PDE). 
Of the various PDE families that hydrolyze cAMP, members of the PDE4 family are 
ubiquitously expressed and serve as cAMP-specific negative regulators of mTOR 
signaling. PDE4’s have also been shown to play key roles in inflammation through 
selective inhibitors and knockdown studies [60]. AMP can come from normal catabolic 
metabolism but may accumulate with glucose deprivation and the subsequent inability to 
efficiently regenerate ATP. 
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The protective, pro-survival cascades and stress responses typically provides more 
time for cellular adaptation to adversity. Depending on the severity and duration, acute 
stress can trigger apoptosis, autophagy, or necrosis. Apoptosis is genetically regulated 
and tightly controlled. Autophagy is a highly conserved catabolic program closely linked 
to nutrient deprivation which allows for nutrient acquisition via degradation of proteins 
and cytosolic components. Necrosis can result from any type of catastrophic devastation 
caused initiated by cell injury and ends with complete cellular destruction and the 
expulsion of cytotoxic waste into the extracellular space [61]. 
Thus, a common view is that while severe Ca2+ dysregulation can promote cell 
death through necrosis, more controlled intracellular [Ca2+] increases induced by milder 
insults promote cell death through apoptosis. [61] (Figure 9). Under stress, 
Ca2+/calmodulin-dependent protein kinase β (CaMMKβ) seems to favor autophagy [61]; 
a process tightly linked to cellular endoplasmic reticulum (ER) and mitochondrial stress 
[62] and by extension mitochondrial AKT, GPS2, and UBC13 [21, 23, 25, 41, 45, 49] 
which could lead to the appearance of fully activated pAKT-S473/T308 at the 
mitochondria, even if not seen at the cytosol. 
	16 
 
Figure 9: Calcium regulates Apoptosis as a second messenger 
 
CaMKKβ was also identified in murine pre-adipocytes and found to activate 
AMPK in response to rising intracellular calcium concentrations [55]. A time dependent 
1 fold increase of pAKT-T308 was attributed to the actions of PDK1 and CaMKKβ in 
serum starved ovarian cancer cells (OVCAR3) [57]. A similar trend was reported using 
cervical cancer cells (HeLA) where investigators sought to understand how glucose 
deprivation impacted AKT phosphorylation and cell survival; because of this restricted 
experimental aim, investigators did not explore the possible role of CaMKKβ. The study 
reports a time-dependent modest increase to both pAKT-T308 (5–6 fold) and pAKT-
S473 (2–5 fold) through a 4-hour starvation period [58]. Across a 16-hour starvation 
period, pAKT-Thr308 increased over 16h of glucose deprivation, whereas pAKT-Ser473 
peaked at about 6h and subsequently declined [58].  
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Downstream of AMPK is the ubiquitously expressed cell cycle inhibitor p21 
activated kinase-2 (PAK2) [31]. PAK2 activity is inversely correlated with AKT activity 
and downregulated by Insulin signaling [31, 32].Specific to the 3T3-L1 cell line, serum 
starvation was found to increase the activity of PAK2 is reported with biphasic activation. 
Within in the first hour of glucose deprivation, PAK2 activity was increased by 2–2.5 
fold within an hour, returned to baseline within 3 hours, and enhanced by 1.5 fold at 5 
hours after starvation [31]. PAK2 is a mTOR-independent TSC1/2 effector [32] 
responsible for downregulating protein synthesis during starvation [31], inducing G1 cell 
cycle arrest [31, 55], or initiating apoptosis through p53 activation [31, 32. 33, 34, 35, 51] 
(Figure 10). 
 
Figure 10: TSC1/2 and PAK2 Function and Regulation. 
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Moreover, the mechanisms by which p53 negatively regulates mTOR involves 
AMP kinase activation and requires the tuberous sclerosis (TSC) 1/TSC2 complex, both 
of which respond to energy deprivation in cells [35]. Through TSC2 knockdown, 3T3-L1 
exhibited mTORC1 driven adipogenesis, PPAR expression, and insulin resistance [26].  
TSC2 knockout in Mouse Embryonic Fibroblasts (MEF) were also characterized with 
insulin resistance and enhanced AMPK activity. Investigators attributed enhanced p53 to 
the loss of TSC2 as a compensatory response to uninhibited and constitutively active 
mTOR; it’s worth noting that while other studies have used p53 deficient models of 
TSC2 Knockout the MEFs used in this study retained their p53 activity [32]. In other 
words, the loss of TSC1/2 inhibition of mTOR can be corrected by upregulating p53 
thereby extending cellular viability when challenged with nutrient depletion and genomic 
instability [32, 33, 37] (Figure 11).  
 
Figure 11: p53 Regulates Cell Cycle and Apoptosis  
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Ubiquitin Mediated Induction of AKT 
Beyond AKT activation by GAG fusion and myristoylation or PI3K mediated 
induction via IS/IGF/EGF, case studies have identified poly-ubiquitinated AKT as a 
driver of rare, pervasive, chronic hypoglycemia and implicated in numerous cancers [16].    
Ubiquitin is a genetically conserved 76 AA polypeptide that can be attached to a substrate 
protein or to an ubiquitin molecule already attached to a substrate via thioester linkages at 
one of 7 lysine (K, Lys,) residues (K6, K11, K27, K29, K33, K48, K63) embedded within 
each ubiquitin molecule [17, 46, 47]. The initial process of ubiquitination begins with an 
Ubiquitin Activating Enzyme (E1) which binds ATP and delivers an ubiquitin subunit to 
a second Ubiquitin conjugating enzyme (E2). Ubiquitin-bound E2 then associates with 
Ubiquitin Protein Ligase (E3) which catalyzes the transfer of ubiquitin from E3 to a 
lysine reside at the target protein. Essentially, E1 provides activation energy, E2 
determines chain topology and function, while E3 provides target substrate specificity 
[19, 20, 68].  
After the initial ubiquitin subunit has been bound to substrate, specific E2 
enzymes can determine chain topology and dictate the function of poly-ubiquitination. 
For example, K48 chains have been extensively characterized as mediators of proteolysis 
in cell cycle control and immune response [17, 46, 47, 67]. Whereas K63 chains have 
recently been implicated in non-proteolytic functioning related to protein trafficking and 
signal transduction pathways [17, 67] (Figure 12).  
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Figure 12: Ubiquitination and Roles in Intracellular Signaling. 
To date, the ubiquitin conjugating protein (UBC13) has been identified as the 
only known major E2 mediator of K63 topology [21, 17] in the cytosolic and nuclear 
compartments. The ability to partition cytosolic from nuclear K63 poly-ubiquitination 
comes from preferential associations of UBC13 with its E3 counterpart. In the cytoplasm, 
UBC13 preferentially associates with the TRAF family of E3 Ligases whereas nuclear 
UBC13 preferentially associates with E3 Ring Ligases RNF8 and RNF168 [45]. 
Based on the findings of an initial study, IGF1 activation was found to directly engage 
Tumor Necrotic Factor (TNF) Receptor Associated Factor 6 (TRAF6) to mediate AKT 
poly-ubiquitination. In conjunction with UBC13, TRAF6 was required for K63 
ubiquitination of AKT on two residues within the PH domain (K8 and K14) [19]. 
Through targeted mutagenesis experiments, K8/K14 were shown to synergistically direct 
AKT translocation to the plasma membrane for phosphorylation and activation. Mutant 
	21 
AKT variants with a single mutation to either ubiquitination site resulted in partial 
reduction of phosphorylated AKT (pAKT), while variants with double mutations resulted 
in a complete loss of pAKT detection. TRAF6 was unable to promote ubiquitination of 
AKT variants completely missing their PH domains [19]. Conversely, case studies have 
shown many cancers and some rare conditions marked by persistent hypoglycemia 
involve a mutation yielding an additional lysine at position 17 of AKT’s PH domain. The 
additional lysine sensitizes AKT allowing it to become hyper-ubiquitinated and 
chronically active [19, 21, 22]. 
Recent publications from our own lab have identified parallel mechanisms of 
UBC13 mediated AKT activity in the adipose tissue of mice when stimulated with insulin 
[21]. Non-degradative K63 poly-ubiquitination was also observed upon EGF stimulation; 
however the associated E3 enzymes were identified as the SKP-SCF complex rather than 
TRAF6 [22].  
Taken together these studies indicate that non-proteolytic AKT ubiquitination, 
mediated by the E2 Ubiquitin Conjugating enzyme (UBC13), is a critical step in AKT 
activation downstream of both Insulin and Growth factor signaling (IGF and EGF) [19, 
21, 22] (Figure 13).  
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Figure 13: Ubiquitination and AKT. 
 
GPS2 can Regulate UBC13 and Modulate AKT activity 
Previous work from our lab indicate that UBC13 activity can be antagonized by 
G-Protein Pathway Suppressor 2 (GPS2); a small (37kD) multi-functional protein 
originally isolated while screening for inhibitors of oncogenic RAS proteins in the Yeast 
Pheromone Response pathway [41, 45].  
GPS2 has both transcriptional and non-transcriptional roles. Its functions in both 
the nucleus and cytosolic compartments rely on a conserved regulatory strategy aimed at 
restricting the formation of K63 chains [21]. Bearing the kinetics of an endogenous 
inhibitor, GPS2 directly inhibits the E2/E3 ubiquitin conjugating complexes 
(TRAF2/Ubc13 in the cytosol and RNF8/Ubc13 in the nucleus) responsible for K63 
chain formation [21].  
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In the nucleus GPS2 has been reported to promote both gene repression and gene 
activation through chromatin remodeling. Through cooperative interactions, nuclear 
GPS2 can complex with a nuclear co-repressor (NCOR) encoded by NCOR1, the 
silencing mediator of retinoid and thyroid hormone receptors (SMRT) encoded by 
NCOR2, and transducing beta-like proteins encoded (TBL1) encoded by TBL1X and 
TBLXR1) [43] forming a stable enzymatically active histone deacetylase complex [41] 
(HDAC3). In addition, independent of interactions with NCoR/SMRT and TBL1/TBLR1, 
GPS2-mediated inhibition of RNF8/Ubc13 stabilizes a Histone Demethylation machinery 
[45] leading to removal of repressive histone marks and activation of target gene 
expression [41, 42]. Similarly, cytosolic GPS2 has been shown to regulate metabolism, 
inflammation, cell cycle progression, mitochondrial biogenesis, and Stress Activated 
Protein Kinases through a similar mechanism of E2/E3 inhibition [21, 25, 41, 42, 43, 44].  
 
Figure 14: GPS2, UBC13, and Cytosolic AKT. 
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 In accord with this inhibitory role, GPS2 was found to restrict AKT non-
proteolytic poly-ubiquitination in adipocytes and thus to play an important role for 
preventing insulin signaling in the fasted state. In absence of GPS2, AKT was found 
hyper-ubiquitinated and constitutively active in mouse adipose tissue in agreement with 
previous findings about the role of K63 ubiquitination in the regulation of AKT 
activation (Figure 14). 
When GPS2 is conditionally deleted in mouse adipose tissue, mice were found to 
develop obesity under normal chow diet [21]. However, increased body weight and 
adiposity was not associated with inflammation or impaired metabolism suggesting that 
loss of GPS2-mediated AKT inhibition plays a positive insulin sensitizing effect [21, 44] 
In accord with constitutively active insulin signaling, gene expression analysis 
revealed a significant increase in the mRNA levels of lipogenic genes in the adipose 
tissues, decreased mRNA expression of hepatic gluconeogenic genes, and elevated 
plasma levels of an insulin sensitizing adipokine in GPS2 deficient mice [21]. These 
observations are consistent with other experiments which show that insulin independent 
lipogenesis (but not glycogenesis) can be triggered by modified AKT, which leads to 
enhanced translocation of GLUT1 and GLUT4 to the plasma membrane in 3T3-L1 pre-
adipocytes; in these experiments, through targeted mutagenesis, the PH Domain was 
removed and a src myristoylation was added to AKT’s amino terminus [40]. Together, 
these results indicate insulin sensitivity is improved in GPS2 deficient WAT because of 
more efficient lipogenesis and decreased lipolysis and gluconeogenesis [21, 44]. 
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Co-localization of Mitochondrial AKT and GPS2 
Our lab has extensively studied the role of GPS2 in the context of metabolic and 
pro-inflammatory pathobiology. Recently, we have shown that mitochondria-to-nucleus 
translocation of GPS2 constitutes a necessary step for the transcriptional response to 
mitochondrial stress. Within the mitochondria, GPS2 can be parceled into 2 distinct 
populations delineated by the presence or absence of post translational sumoylation. 
Unmodified GPS2 was localized to the mitochondrial matrix; while modified GPS2 
(Sumoylated) was found to localize to the outer membrane of the mitochondria [25]. 
Interestingly, like GPS2, some reports indicate AKT localizes to the 
mitochondrial matrix and outer membranes. Consistent with previously published data on 
cytosolic AKT activation, growth factor treatment and exposure to heat shock caused 
significant increases in mitochondrial AKT phosphorylation (activation) within minutes 
of stimulation [49].  
Based on our recent work indicating that GPS2 localizes to the same 
compartment, we hypothesized that UBC13-mediated ubiquitination contributes to AKT 
regulation in the mitochondria with GPS2 serving as negative regulator.  To investigate 
this hypothesis, we asked whether UBC13 is required to regulate AKT activation in the 
mitochondria and whether the absence of GPS2 facilitates AKT activation at the 
mitochondria. While the exact mechanism behind mitochondrial AKT regulation at the 
outer mitochondrial membrane remains unknown, it has been previously attributed to 
downstream cytosolic effectors of PI3K [49]. Given the mitochondrial outer membrane is 
plasma membrane facing, we speculate that non-degradative ubiquitination could be 
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favoring the recruitment of AKT to the plasma membrane which is a limiting step for 
pathway activation in a PI3K dependent fashion. 
  
	27 
METHODS  
 
Cell culture  
In experiment 1, 3T3-L1 pre-adipocytes (American Type Culture Collection) 
were cultured in high glucose Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% Newborn Bovine Calf Serum (Hyclone) under 5% CO2. Cells 
were serum starved for 6 hours and treated with UBC13 inhibitor (Sigma) prior to 100nM 
Insulin (Life Technologies) treatment for 5 minutes prior to cellular harvest.  
In experiment 2, 3T3-L1 pre-adipocytes (American Type Culture Collection) 
were cultured in high glucose Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% Newborn Bovine Calf Serum (Hyclone) under 5% CO2. Cells 
were transfected with MISSION siRNA Universal Negative control (Sigma) or siGPS2 
(#s80309, 20 nM, Ambion) using JetPrime (Polyplus-Transfection) according to the 
manufacturer’s instructions. After 24 hours, fresh 10% BCS-DMEM was applied for 
another 24 hours. On the day of harvest, cells were treated with UBC13 inhibitor (Sigma) 
for 6 hours prior to harvest. 
In experiment 3, 3T3-L1 pre-adipocytes (American Type Culture Collection) 
were cultured in high glucose Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% Newborn Bovine Calf Serum (Hyclone) under 5% CO2. Cells 
were transfected with MISSION siRNA Universal Negative control (Sigma) or siGPS2 
(#s80309, 20 nM, Ambion) using JetPrime (Polyplus-Transfection) according to the 
manufacturer’s instructions. After 24 hours, fresh 10% BCS-DMEM was applied for 
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another 24 hours. On the day of harvest, cells were serum starved for 6 hours and treated 
with PI3K inhibitor LY294002 (#s1105, 10 uM, Selleckchem) for 4 hours prior to 
harvest. 
Cells were collected in PBS, spun down at low speed (1000rpm) for 5 minutes, 
and aspirated. Remaining pellets were stored in at -80 in preparation for Subcellular 
Centrifugal Fractionation.  
Protein Extraction, Subcellular Fractionation, and Protein Detection 
For cytoplasmic, mitochondrial and nuclear extracts fractionation cells were 
rinsed in PBS, harvested and re-suspended in gradient buffer (10 mM HEPES pH 7.9, 
1mM EDTA, 210 mM Mannitol, 60mM Sucrose, 50 mM NaF, 2 mM Na2VO3, 0.2 mM 
PMSF and 1x protease inhibitors cocktail) then homogenized via 10 passages through 
25G syringe followed by low speed centrifugation for 10 min. 
The nuclear pellet was incubated for at least 20 min in Nuclear Extract Lysis 
buffer (20mM TRIS/HCL pH 8.0, 25% glycerol, 420mM NaCl, 1.5mM MgCl2, 0.2mM 
EDTA, 50mM NaF, 2mM Na2VO3, 0.2 mM PMSF and 1x protease inhibitor mix) while 
the supernatant was recovered and subjected to high-speed centrifugation to separate the 
mitochondrial pellet from the cytoplasmic fraction. The mitochondrial pellet was 
incubated for 15 min in lysis buffer (50 mM Tris/HCl pH 8, 300 mM NaCl, 1mM EDTA, 
50 mM NaF, 2 mM Na2VO3, 0.2 mM PMSF and 1x protease inhibitors cocktail).  
Protein concentrations were analyzed using the BioRad Bradford assay and 
normalized for protein loading for each respective fraction. Extracts were boiled in SDS 
sample buffer and loaded 10% Mini-PROTEAN TGX gels (BioRad), prior to transfer 
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onto PVDF membranes (Millipore) and western blotting following standard protocols. 
Blotting with markers of the different fractions (Beta-Tubulin for cytosolic extract, 
mtHSP70 or ATP-5b for mitochondrial extracts) was used to assess purity.   
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RESULTS 
UBC13 is a positive regulator of AKT activity in the Mitochondria 
To determine if GPS2 can regulate anabolic metabolism within the mitochondrial 
compartment through modulation of AKT, we will first need to ascertain a role for 
UBC13 activity in the activation of mitochondrial AKT.  
To test this, 18 plates of 3T3-L1 were grown to moderate confluency, serum 
starved, and divided into Positive control (n = 6), Negative control (n = 6), and 
experimental groups treated with UBC13 inhibitor (n = 6). After 4 hours of serum 
starvation, the positive control and experimental groups were insulin treated for 5 
minutes. All cells (n = 18) were harvested following the insulin exposure and separated 
into cytosolic, mitochondrial, and nuclear lysates via centrifugal subcellular fractionation. 
Following protein quantification via the BioRad Assay, 30 micrograms from each 
respective fractionation was further separated using Western Blots, transferred to PVDF 
membranes, and probed with antibodies (Total AKT, pAKT-S473, ATP-5 Beta, and Beta 
Tubulin), and developed using enhanced chemiluminescence (Figure 15). 
The resulting Western Blot depicted in Figure 15 depicts the cytosolic, 
mitochondrial, and nuclear fractions of each treated group (Positive Control, Negative 
control, Experimental Group) across the X axis. Similarly, the primary antibody probe is 
listed vertically along the Y axis. 
As expected, the levels of Total AKT are relatively consistent within each 
fractionated group. In agreement with our expectations, AKT activity (seen as a black bar 
in the pAKT-S473 row) is absent within and between serum starved cytosolic negative 
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controls, and present within and between cytosolic serum starved and insulin treated 
positive controls.  
Notably, while the insulin mediated activation has been extensively characterized 
regarding cytosolic AKT, the major finding of Figure 15 is seen in the mitochondrial 
fractions. Similar to the cytosolic fraction, insulin treatment yields a strong pAKT-S473 
signal in the mitochondrial serum starved positive control; suggesting that AKT localized 
to the mitochondria responds to insulin in a separate but coordinated way to cytosolic 
AKT. Additionally, the robust pAKT-S473 signal can be attenuated when treated with a 
UBC13 inhibitor in both the cytosolic and mitochondrial fractions; suggesting the 
mechanism of AKT activation is not only coordinated between distinct cellular partitions, 
but also relies on a similar, conserved mechanism of non-proteolytic poly-ubiquitination. 
Taken together, these findings validate the experimental design by reproducing the 
expected results for cytosolic AKT activity patterns and extend the existing paradigm of 
insulin signaling to the mitochondrial and nuclear compartments. 
Lastly, ATP-5b is a mitochondrial loading control and should only appear in the 
mitochondrial fraction. Similarly, Beta-Tubulin is a cytosolic loading control and should 
only appear in the cytosolic fraction. Blots for these two markers indicate that the 
separation technique was effective and the fractions of cell lysate are clean as evidence 
by appropriate localization of the loading controls. See Appendix for experimental 
designs and magnified data. 
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Figure 15: UBC13 is positive regulator of Mitochondrial AKT.  
3T3-L1 Pre-adipocytes were starved, fractionated, and run through a Western Blot. 
The membranes were then probed with Total AKT, pAKT-S473, ATP-5B, and Beta-
Tubulin primary antibodies. (A) We see that within a given fraction, the amount of 
Total AKT is roughly the same. (B) Across each respective fraction, we see an 
emerging pattern of an expected absent signal from cells only subject to serum 
starvation. This is followed by a relatively robust signal in the starved, insulin treated 
fractions. The attenuated signal in the starved, insulin treated, E3 enzyme inhibited 
(UBC13i = UBC13 inhibitor) fractions indicate UBC13 as a positive regulator of AKT 
activity. (C + D) To ensure sample purity between the fractions, ATP-5Beta was used 
as a mitochondrial marker; Beta-Tubulin was similarly used as a cytosolic marker. 
Because the signals from each respective loading control are mutually exclusive and 
appear only in their designated fraction, we can conclude the cell separation technique 
was efficient with no cross contamination.  
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GPS2 is an Endogenous inhibitor of mitochondrial UBC13 
We know from previous studies that GPS2 has been shown to attenuate the 
potency of UBC13 and subsequent AKT activity from whole cell lysates [44]. Based on 
the findings of Experiment 1, we can conclude that UBC13 behavior in the mitochondria 
mirrors that of Cytosolic UBC13. After the role of mitochondrial UBC13 had been 
defined, we next wanted to know if mitochondrial GPS2 would also retain its role as an 
endogenous inhibitor at the mitochondria. 
To test this, 18 plates of 3T3-L1 were again grown to moderate confluency and 
divided into non-starved Positive control (n = 6), Negative control (n = 6), and 
experimental groups treated with UBC13 inhibitor (n = 6). Non-starved negative controls 
(n =6) were transfected with scrambled (random, non-specific) RNA. Positive control and 
Experimental groups (n =12) were transfected with siGPS2. Per JetPrime protocol, cells 
were incubated and left undisturbed for 24 hours. The next day, the cell culture media 
was refreshed and the cells were again allowed to incubate undisturbed for another 24 
hours. 44 hours after siGPS2 transfection, the experimental group was incubated with 
UBC13 inhibitor for a duration of 4 hours.  All cells (n = 18) were harvested 48 hours 
after transfection and separated into cytosolic, mitochondrial, and nuclear lysates via 
centrifugal subcellular fractionation. Following protein quantification via the BioRad 
Assay, 30 micrograms from each respective fractionation was further separated using 
Western Blots, transferred to PVDF membranes, and probed with antibodies (Total AKT, 
pAKT-S473, mtHSP70, and Beta Tubulin), and developed using enhanced 
chemiluminescence (Figure 16). 
	34 
The resulting Western Blot shown in Figure 16 depicts the cytosolic and 
mitochondrial fractions of each treated group (Positive Control, Negative Control, 
Experimental Group) across the X axis. Similarly, the primary antibody probe is listed 
vertically along the Y axis. 
As expected, the levels of Total AKT are relatively consistent within each 
fractionated group. The absence of a pAKT signal is also to be expected within the 
negative control groups which were only subjected to transfection with scrambled RNA. 
In agreement with the previously published lab data, a strong pAKT-S473 signal 
appears in the non-starved cytosolic positive control groups subject to siGPS2 
Transfection [21, 44, 45]. The signal completely disappears in the experimental group of 
non-starved 3T3-L1 transfected with siGPS2 and treated with UBC13 inhibitor, 
confirming that GPS2 knockdown by transfection is sufficient to allow for enhanced 
AKT activity under basal conditions without the additional impetus of an AKT agonist 
and that activation of AKT in absence of GPS2 is Ubc13-dependent.  
Interestingly, the same pattern of pAKT-S473 signal is mirrored in the 
mitochondrial fraction. This indicate that the oppositional roles of UBC13 and GPS2 are 
playing a key role in regulating AKT activation not only in the cytosolic fraction but also 
in the mitochondrial compartment.  
Lastly, ATP-5b is a mitochondrial loading control and should only appear in the 
mitochondrial fraction. Similarly, Beta-Tubulin is a cytosolic loading control and should 
only appear in the cytosolic fraction. Blots for these two markers indicate that the 
separation technique was effective and the fractions of cell lysate are clean as evidence 
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by appropriate localization of the loading controls. See Appendix for experimental 
designs and magnified data. 
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Figure 16: GPS2 is a negative regulator of UBC13 and Mitochondrial AKT. 3T3-
L1 Pre-adipocytes were transfected in cell culture media, fractionated, and run through 
a Western Blot. The membranes were then probed with Total AKT, pAKT-S473, 
mtHSP70, and Beta-Tubulin primary antibodies. (A) We see that within a given 
fraction, the amount of Total AKT is roughly the same. (B) Between the Cytosolic and 
Mitochondrial fractions, the pAKT-S473 manifests only in the GPS2 knockdown 
population of cells. The mitochondrial signal indicates that GPS2 behaves as a 
negative regulator of AKT activity at the mitochondria and validates the same 
inhibitory behavior of GPS2 in the cytosol. This blot also validates the role of UBC13 
as a positive regulator of AKT activity in the mitochondria because when the negative 
regulator (GPS2) is knocked down and the positive regulator is inhibited, the signal 
for pAKT is completely absent in both the cytosol and mitochondrial fractions. (C + 
D) To ensure sample purity between the fractions, ATP-5Beta was used as a 
mitochondrial marker; Beta-Tubulin was similarly used as a cytosolic marker. Because 
the signals from each respective loading control are mutually exclusive and appear 
only in their designated fraction, we can conclude the cell separation technique was 
efficient with no cross contamination.  
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UBC13 mediated regulation of AKT is partially PI3K dependent 
Once the relationship between GPS2, UBC13, and AKT had been established at 
the mitochondria the next logical step would be to determine whether or not this 
secondary layer of post-translational modification and regulation was dependent on PI3K; 
a key contributor to the towards primary AKT regulation by phosphorylation rather than 
ubiquitination.  
The resulting Western Blot depicted in Figure 17 depicts for cytosolic and 
mitochondrial fractions of each treated group (Positive Control, Negative Control, 
Experimental Group) across the X axis. Similarly, the primary antibody probe is listed 
vertically along the Y axis.  
The preliminary data depicted as Figure 17 is a replicate of the first attempt (not 
shown) using the same experimental design. It was performed a second time because of 
the unexpected appearance of a signal in the pAKT-S473 negative controls from both 
fractions. Before completing a second attempt of this experiment, a new batch of 
previously frozen cells were unfrozen and allowed to progress through 10 passages 
before being used for this experiment. Additionally, the protocol was re-checked, the 
amount of loaded protein was increased from 30 to 34 micrograms, and a new bottle of 
Starvation Media was placed in the refrigerator and unopened until 44 hours post-
transfection when the cells would need to be starved for this experiment.  
This third experiment was conducted in a similar way to the second experiment in 
that again, 18 plates of 3T3-L1 were grown to moderate confluency and divided into 
Positive control (n = 6), Negative control (n = 6), and experimental groups treated with 
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PI3K inhibitor (n = 6). Negative controls (n =6) were transfected with scrambled 
(random, non-specific) RNA. Positive control and Experimental groups (n =12) were 
transfected with siGPS2. Per JetPrime protocol, cells were incubated and left undisturbed 
for 24 hours. The next day, the cell culture media was refreshed and the cells were again 
allowed to incubate undisturbed for another 24 hours. 42 hours after transfection 
starvation media was applied to all groups. 44 hours after siGPS2 transfection, the 
experimental group was incubated with PI3K inhibitor for a duration of 4 hours. All cells 
(n = 18) were harvested 48 hours after transfection and separated into cytosolic, 
mitochondrial, and nuclear lysates via centrifugal subcellular fractionation. Following 
protein quantification via the BioRad Assay, 34 micrograms from each respective 
fractionation was further separated using Western Blots, transferred to PVDF 
membranes, and probed with antibodies (Total AKT, pAKT-S473, mtHSP70, and Beta 
Tubulin), and developed using enhanced chemiluminescence. 
Unexpectedly, but consistent with the first attempt at Experiment 3 (data not 
shown), a weak pAKT-S473 signal is detected in the negative control lane (siRNA 
transfection and serum-starved only) of both fractions. Consistent with the findings of 
Experiment 2, we see a well-defined signal pAKT-S473 signal from the positive control 
lanes receiving only siGPS2 transfection. More importantly, the signal disappears in the 
experimental lanes which were subjected to the siGPS2 transfection and treated with 
PI3K inhibitor in the cytosolic fraction. In the mitochondrial fraction pAKT-S473 does 
not completely disappear but does appear weaker. This could suggest that an alternative 
pathway could contributes to UBC13 mediated regulation of AKT at the mitochondria 
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because the pAKT signal is attenuated when treated with the PI3K inhibitor; in contrast 
to the cytosolic fraction showing a complete absence of the pAKT signal. 
To re-affirm the validity of pAKT-S473 signal, I re-probed the same blot with 
mouse derived Anti-pAKT-S473. This particular antibody seems to be less specific to its 
antigen because it cross-reacts with our DNA ladders; that being said the mouse-pAKT-
S473 did not react at all with the cytosolic fraction but did reveal a similar manifestation 
of pAKT-S473 signal in the mitochondrial lysate. After using the mouse antibody, I 
stripped the membrane (Thermo Scientific™ Restore™ Plus Western Blot Stripping 
Buffer) per the manufacturer’s recommended instructions and re-probed with rabbit 
derived anti-pAKT-S473. The resulting ECL had the same signal shown by the first 
rabbit and mouse probings.  
The membrane had to be stripped a second time before probing with our rabbit 
derived Total-AKT antibody. Based on the ECL of Total AKT, it appears that the 
negative controls may have had less protein loaded, relative to the positive control and 
experimental groups. Despite this, it’s worth noting that the positive controls and 
experimental groups seem to be roughly equivalent. 
Anticipating the first membrane would be probed and stripped multiple times, I 
made plans to perform the loading controls on a separate blot from the Mouse/Rabbit 
AKT membranes from the remaining lysate.  
Taken together, the Total AKT probe shows that the positive control and 
experimental groups were loaded similarly; mutually exclusive from the negative 
controls. The Beta-Tubulin signal supports that observation and collectively indicates the 
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separation technique was efficient and the fractions were free of cross-contamination. 
Similarly, the ATP-5B demonstrates the mitochondrial fractions to be free of cross 
contamination and equally loaded. See Appendix for experimental designs and magnified 
data. 
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Figure 17: UBC13 and Mitochondrial AKT may partially rely on PI3K. 3T3-L1 Pre-
adipocytes were transfected, starved, fractionated, and run through a Western Blot. The 
membranes were then probed with Total AKT, pAKT-S473, ATP-5B, and Beta-Tubulin 
primary antibodies. WB3.1 (A-C) was probed with Rb-pAKT and Ms-AKT, stripped, and 
probed a final time with Rb-Total AKT. WB3.2 (D-E) was probed with in-house Rb-
GPS2, stripped, and re-probed with Ms-Beta Tubulin and Rb-ATP-5B. To ensure sample 
purity between the fractions, ATP-5Beta was used as a mitochondrial marker; Beta-
Tubulin was similarly used as a cytosolic marker. Because the signals from each 
respective loading control are mutually exclusive and appear only in their designated 
fraction, we can conclude the cell separation technique was efficient with no cross 
contamination.  
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siGPS2 Knockdown Transfection was efficient 
Lastly, to ensure that these experiments were indicative of the impact of GPS2 on 
UBC13 and AKT activity, it is important to show that the GPS2 targeted knockdown by 
transfection was efficient. To ascertain the efficient knockdown of GPS2, the remaining 
lysate from Experiment 2 [17 µg total, and verifiably clean fractionation based on the 
Beta Tubulin/mtHSP70 ECL] was used in second western blot and probed with in-house 
rabbit anti-GPS2. While the experimental group (siGPS2 transfection and treated with 
UBC13 inhibitor) seems to be less than the lower limits of detection for that particular 
imager, the signal from the negative control (Scramble RNA transfected) appears to be 
darker and better defined than the signal detected within the cytosolic positive control 
(siGPS2 transfected) group. This provides supporting evidence that the knockdown of 
GPS2 was efficient.  
Similarly, the remaining lysate from Experiment 3 [34 µg total, and verifiably 
clean fractionation based on the Beta Tubulin/ATP-5b ECL] was used in a second 
western blot and probed with in-house rabbit anti-GPS2. At the 37kDa mark we again see 
that the negative control group (Scramble RNA transfected) is darker and better defined 
relative to the positive control (siGPS2 transfection). This provides supporting evidence 
that the knockdown of GPS2 was efficient. The Mitochondrial Experimental Group 
(siGPS2 transfection and treated with PI3K inhibitor) was not included because there 
wasn’t enough lysate remaining after the first western blot depicted in Figure 18. See 
Appendix for experimental designs and magnified data. 
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Figure 18: Efficient GPS2 Knockdown. 3T3-L1 Pre-adipocytes were transfected, 
starved, fractionated, and run through a Western Blot. (A) Remaining cytosolic lysate 
from UBC13 and GPS2 inhibited cells was probed with in house anti-GPS2. Bands 
around 37kDa indicate a reduction in GPS2 signal between cells transfected with 
scrambled RNA and cells transfected with siGPS2. (B) Remaining mitochondrial lysate 
from PI3K and GPS2 inhibited cells was probed with in house anti-GPS2. Bands around 
37kDa indicate a reduction in GPS2 signal between cells transfected with scrambled 
RNA and cells transfected with siGPS2.  
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DISCUSSION 
 Taken together, these experiments have contributed to the growing body of 
knowledge as it relates to the network of AKT regulation by non-degradative poly-
ubiquitination at the mitochondria. In experiment one, we saw that UBC13 facilitates 
phosphorylation at AKT’s activation loop (S473). This is likely a result of 
conformational changes engendered by the deposition of K63 ubiquitin chains via 
UBC13 and its associated TRAF proteins, and consistent with the “Induced Fit” theory of 
enzyme-substrate catalysis. UBC13 activity has been previously shown to regulate 
cytosolic AKT in response to Insulin or growth factor. While AKT has been previously 
reported to localize at the mitochondria, its regulatory mechanisms remain largely 
unexplored. Our data provides one of the first glimpses into how mitochondrial AKT can 
be regulated by demonstrating a positive correlation between UBC13 activity and AKT 
activity. We also saw, in parallel to cytosolic and mitochondrial fractions, a similar 
pattern of AKT phosphorylation from the nuclear lysate demarcated in red. Under normal 
conditions, active mTORC1 is known to phosphorylate AKT and upregulate peroxisome 
proliferator-activated receptor gamma (PPARγ) transcription and translation [26]. PPARγ 
belongs to a subfamily of orphan nuclear receptors downstream of the insulin receptor 
whose effectors include AKT, MAPK, and GSK3 among many other [27] and plays a 
central regulatory role in adipocyte differentiation through its known interactions with 
GPS2 associated co-repressors such as NCor and SMRT [28].  
Insulin driven AKT enhancement in the nucleus also coincides with a potential 
role for UBC13 mediated activation of nuclear AKT which would metabolically shift an 
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adipocyte towards adipogenesis in the presence of mitogenic signaling and nutrient 
excess. While this question is beyond the scope of this project, it is circumstantially 
supported with documented UBC13/GPS2 activity in the nucleus [21] as well as the 
presence of nuclear AKT substrates such as the FOXO Family of transcription factors 
and the GPS2 binding co-activator p300 [23,24,25] 
Upon establishing a regulatory role for UBC13 on mitochondrial AKT, the second 
experiment was designed to ascertain the role of GPS2; previously shown to act as an 
endogenous inhibitor of cytosolic UBC13. To determine if GPS2 could inhibit UBC13 in 
the mitochondria, and by extension modulate AKT activity, we evaluated the impact of 
GPS2 knockdown on basal activity of AKT in non-starved pre-adipocytes. Consistent 
with previously published lab data exploring the interactions of UBC13, GPS2, and AKT 
in the cytosol, Experiment 2 offers evidence supporting the hypothesized antagonistic 
role of mitochondrial GPS2 while also reaffirming mitochondrial UBC13 as a positive 
regulator of AKT phosphorylation at the mitochondria. These results could also suggest 
that GPS2 mediated inhibition of AKT activity is a necessary safeguard against chronic 
hypoglycemia and dysregulated metabolism by ensuring AKT is not constitutively 
activated under basal metabolic conditions; this finding is also supported by previous 
publications from our lab [21, 25, 44, 45].   
Lastly, the findings of Experiment 3 suggest mitochondrial AKT regulation is 
modulated by an intracellular signaling cascade(s) outside of the canonical Insulin-PI3K 
network. This conclusion is evidenced by unexpected pAKT-S473 in the starved negative 
controls treated indicating an alternative protective metabolic program, reliant upon the 
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actions of AKT, had been inadvertently activated. Such cellular programs could include 
stress responses to glucose deprivation and cytotoxicity associated with PI3K inhibition. 
In accordance with the proposed role of CaMMKβ, increasing cytotoxicity could 
have intracellular calcium release which would have oriented the cell towards autophagy 
while contributing to p53 upregulation. CaMMKβ has been associated with calcium 
dependent AKT activation in vitro at pAKT-T308 but not pAKT-S473 [55, 57, 61]; 
however our experimental design which favors pAKT-S473 could extend the window of 
PDK1/mTORC2 catalysis of AKT. Once the toxicity becomes unsustainable, p53 would 
recruit DNA-dependent Protein Kinase (DNA-PK); a serine threonine kinase and 
indicator of DNA double stranded breaks and Non-Homologous End Joining repair [34]. 
Interestingly, DNA-PK can activate AKT through S473 phosphorylation, and pAKT-
S473 is strongly correlated with p53 stability [34].   
The nexus around AMPK activation (cAMP, PAK2, LBK1, CaMKKβ, 
mTORC2, and SGK1) was likely triggered following prolonged (3+ hours for these 
particular cells [31, 32]) glucose deprivation and could lead to AKT phosphorylation 
by a number of kinases. Based on the results from Experiment 2 in unstarved cells, 
GPS2 inhibition could have bolstered the AKT activity; in turn, this could trigger a more 
robust invocation of TSC agonists and mTOR antagonists to shut down anabolic 
metabolism during starvation[31, 32 35, 37, 51, 52, 53]. 
Simultaneously vulnerable cells, such as those caught in S phase at the time of 
starvation or PI3K treatment, could have become necrotic. The release of Calcium 
activated hydrolases upon necrotic cellular death would only further poison the media 
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[61] and threaten the genomic stability of neighboring cells (already challenged with 
starvation) within the same petri dish.    The combined stress of starvation, the inherent 
cytotoxicity of LY294002 (PI3K inhibitor), and the necrosis of neighboring cells could 
upregulate p53 which would orient pre-adipocytes towards autophagy [61]. 
Eventually, escalating toxicity and a paltry supply of energetic resources would pose a 
threat to genomic stability leading to DNA-dependent Protein Kinase (DNA-PK) 
recruitment by p53. DNA-Pk activity coincides with Non-Homologous End Joining 
repair of double-stranded DNA breaks; DNA-PK has been shown to phosphorylate AKT 
at S473, and pAKT-S473 is strongly correlated to p53 stability [34]; this observation in 
conjunction with the finding that UBC13 can also target and enhance PI3K, coupled with 
GPS2 inhibition could create circumstances which explain the findings from Experiment 
3. [19, 20]. 
In an attempt to circumnavigate the stress response and/or stress related protein 
kinases, the third experiment should be repeated without serum starvation. Alternatively, 
a time course study and qPCR may be helpful in determining the relative levels of GPS2 
(to make sure the knockdown was efficient) and JNK (as another gauge of cellular stress 
and GPS2 mediated substrate). Western Blotting with pAKT-S473, pAKT-T308, Total 
AKT, GPS2, K-63 chains, and loading controls would provide a more complete picture of 
cellular metabolism and a more precise indicator of how GPS2 and UBC-13 affect AKT 
Activity at the mitochondria.  
If the resultant data from a non-starved replicated Experiment 3 bear no signal in 
the pAKT lanes of negative controls, then the signal from my data is likely due to a 
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robust, protective, pro-survival mechanism wrought by the inherent cytotoxicity 
associated with transfection, starvation, and PI3k inhibition. It’s possible that UBC13 
inhibition is less cytotoxic because it has a narrowly defined role as an E3 Ligase and acts 
on a relatively limited number of known substrates. In contrast, PI3k as a superfamily of 
proteins has multiple isoforms which drive many other pleiotropic effectors (such as 
AKT with at least 40 downstream substrates). Therefore, PI3K disruption is likely to be 
more detrimental, relative to UBC13 inhibition, to the health of cell culture. If cells are in 
the process of dying or undergoing apoptosis, this could raise the background of Western 
Blotting and further complicate the identification of true signals. If the pAKT signal 
remains, but is weaker it may be advisable to consider PI3k knock-out by transfection. 
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APPENDIX 
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